Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II/III Clinical Study Evaluating the Efficacy and Safety of BAT4406F Injection in Patients With Minimal Change Disease/Focal Segmental Glomerulosclerosis

NCT07499700 is registered in ClinicalTrials.gov with Bio-Thera Solutions as lead sponsor.

NCT NCT07499700
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07499700 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II/III Clinical Study Evaluating the Efficacy and Safety of BAT4406F Injection in Patients With Minimal Change Disease/Focal Segmental Glomerulosclerosis
Lead sponsor
Bio-Thera Solutions
Phase
Phase 2/3
Overall status
Recruiting
Start date
October 26, 2025
Completion date
November 26, 2030
Enrollment
192 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

focal segmental glomerulosclerosis (fsgs), minimal change disease (mcd)